<img src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/Oav2oYJbUg04UBRt99eGJKU9Py6hsXxiPILbUvgWJ7CcwAA/641?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="Image" original-src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/Oav2oYJbUg04UBRt99eGJKU9Py6hsXxiPILbUvgWJ7CcwAA/641"/>
As the growth rate of conventional medical equipment bidding and procurement gradually slows down, and the normalization of centralized procurement policies forces the industry to seek a second growth curve, China's in vitro diagnostics (IVD) industry stands at a critical crossroads. In Guangzhou, a wave of industrial transformation driven by &#34;data&#34; is surging.
When the Southern Metropolis Daily video reporter entered the headquarters of KingMed Diagnostics on Guangzhou International Biological Island, what they saw was no longer just a cold testing assembly line, but a real-time data live broadcast screen.
On the screen, yellow light spots represent business coverage, red light spots mark key hospitals, and the positions of cold chain logistics vehicles and the status of samples in transit are clear at a glance. This is not only a visualization of operational management but also a microcosm of Guangzhou's leap towards &#34;intelligent data&#34; in the IVD industry.
Why IVD? A Strategic Leap from &#34;Foundation&#34; to &#34;Ace&#34;
The biopharmaceutical and health industry is a strategic pillar industry in Guangzhou's &#34;12218&#34; modern industrial system. After experiencing the tempering of a &#34;V-shaped&#34; reversal in 2025, Guangzhou's choice for future tracks has become increasingly clear: no &#34;flood irrigation,&#34; but precise strikes.
Based on industrial foundations and future trends, Guangzhou has precisely locked in six core tracks: IVD, traditional Chinese medicine, medical institution preparations, nuclear medicine, cell and gene therapy, and brain-computer interfaces, striving for &#34;breakthroughs at single points and blooming at multiple points.&#34; Among them, IVD is listed as the top core track.
Guangzhou's confidence primarily comes from its tangible &#34;hard foundation.&#34; It is home to over 6,500 biopharmaceutical companies, with more than 7,600 medical institutions and 191 million annual medical visits forming a natural &#34;testing ground.&#34; Especially in the IVD field, Guangzhou's third-party medical testing occupies the first market share in the country, establishing Guangzhou's absolute voice in this field.
However, being number one in market share does not mean a long-term &#34;laying down to win.&#34; For government departments, the reason for focusing on the IVD track is based on a forward-looking judgment of future medical forms.
With the improvement of people's health awareness and the intensification of population aging, the disease diagnosis port is moving forward, and in vitro diagnostics have become the source of 70% of information in clinical decision-making. Whoever masters the most advanced diagnostic technology holds the key to precision medicine.
Guangzhou's strategic intention is clear: relying on a vast clinical sample resource, utilizing artificial intelligence large model technology, to upgrade from a traditional &#34;testing province&#34; to a &#34;data strong province&#34; and &#34;intelligent diagnosis highland.&#34; This is not only to consolidate industrial advantages but also to seize the high ground in future medical technology standards and data asset transactions.
Guangzhou's Approach: Policy &#34;1+N&#34; and Platform &#34;Three Jumps&#34;
After selecting the track, how to exert force? Guangzhou's approach shows distinct systematic characteristics
At the policy level, Guangzhou has established a &#34;1+N&#34; precise support system. With the &#34;Several Policy Measures for Promoting High-Quality Development of Biomedicine in Guangzhou&#34; issued as Document No. 1 by the municipal government in 2024 as the overarching framework, substantial financial support is being provided to facilitate the landing of top global technologies.
Subsequently, regarding the IVD industry, Guangzhou is accelerating the introduction of a special policy package, along with &#34;N&#34; measures such as an innovative drug and device catalog, medical insurance support, and application promotion, covering the entire chain from achievement transformation, administrative approval to market expansion. This &#34;customized&#34; policy supply makes the enterprise benefit policies no longer just slogans, but tangible dividends.
More importantly, it involves the physical space for carrying and the integration of the innovation chain.
Nandu N Video reporters noted that Guangzhou is playing a grand game of &#34;platform relay.&#34; At the front end, relying on large scientific facilities like the Human Cell Lineage and the Guangzhou National Laboratory, it tackles cutting-edge basic science; at the mid-end, platforms like the Guangdong Provincial Innovation Medical Achievement Transformation Center are responsible for converting laboratory concepts into patentable industrial applications; at the back end, the four major value parks of Huangpu, Nansha, Yuexiu, and Liwan, along with specialized IVD characteristic industrial parks, provide the &#34;carriers&#34; for project implementation.
This closed-loop design from &#34;source innovation&#34; to &#34;transformation acceleration&#34; to &#34;industrial landing&#34; addresses the challenges of transforming biomedical achievements. Especially for the IVD industry, this layout allows an idea for a testing reagent to quickly find clinical validation resources, approval guidance support, and large-scale production bases.
Corporate Response: KingMed Medical “ AI IN ALL ” and Ecological Collaboration
The favorable policies ultimately rely on enterprises to take root and implement them. In Guangzhou, leading enterprises represented by KingMed Medical are responding to this transformation with practical actions, and their path holds significant sample value.
<img src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OEN1GDDyMvbYW8quwyiIkRBiYD2wWMA39aHHnGRRmx8vsAA/641?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="Image" original-src="https://imageproxy.pbkrs.com/https://inews.gtimg.com/om_bt/OEN1GDDyMvbYW8quwyiIkRBiYD2wWMA39aHHnGRRmx8vsAA/641"/>
Inside KingMed Medical's laboratory.
Facing the overlap of economic cycles and medical policy cycles, in 2025, KingMed Medical launched its second five-year digital transformation, proposing the &#34;AI IN ALL&#34; strategy. This stems from the company's confidence built over more than 30 years in the medical testing field.
Relying on over 3 billion cases of medical testing big data, KingMed Medical, on one hand, integrates new-generation information technology and biotechnology, allowing AI to better assist doctors by providing intelligent report interpretations, specialized auxiliary diagnosis and treatment services, etc. Among these, the development of an AI cervical cancer auxiliary screening model for pathologists takes on the most time-consuming task of slide reading, significantly reducing the interpretation speed of pathological slides to one-tenth of the original.

Staff at KingMed Diagnostics are interpreting pathology slides.
On the other hand, KingMed Diagnostics is also continuously exploring the path of marketization of data elements, having pioneered the entire process of on-site trading of data products within the industry. Currently, 32 data products have been listed on data exchanges in Guangzhou, Beijing, and Shanghai.
In the Baiyun District of Guangzhou, another model of exploration is also underway. Dian Diagnostics is collaborating with the First People's Hospital of Guangzhou Baiyun Hospital to build a medical testing center for the Western Medical Group, implementing a centralized operation of &#34;grassroots sampling, central testing, and mutual recognition of results.&#34; This not only represents a downward shift in services but also promotes the equalization of high-quality medical resources through a regional information integration platform.
Standing at the threshold of the &#34;14th Five-Year Plan,&#34; the competitive logic of Guangzhou's IVD industry is undergoing profound changes. From top-level design at the policy level to platform construction at the carrier level, and to digital intelligence breakthroughs at the enterprise level, Guangzhou is playing a strategic game aimed at mastering the future discourse power in healthcare. This city, once known as the &#34;Capital of Testing,&#34; is rapidly advancing towards becoming the &#34;Capital of Smart Diagnosis.&#34;
Planning: Wang Weiguo, Li Yang
Coordination: Yin Lai, Wang Daobin, You Manni
Reporting: Nandu N Video Reporter Wu Yueming

Guangzhou is promoting the transformation of the in vitro diagnostics (IVD) industry, striving to transition from a "sample powerhouse" to a "data strong city." As the growth rate of medical equipment bidding and procurement slows down, Guangzhou focuses on six core tracks including IVD, leveraging its rich clinical sample resources and artificial intelligence technology to achieve a "digital intelligence" upgrade for the industry. Guangzhou has more than 6,500 biopharmaceutical companies and over 7,600 medical institutions, leading in market share in the IVD field. The government hopes to master key technologies for future healthcare through precise development

Guangzhou plans a new track in IVD: from "sample powerhouse" to "data strong city"